News | Magnetic Resonance Imaging (MRI) | April 13, 2016

Toshiba MRI Tapped for Study on Cerebral Microbleeds in High School Football Players

Study will seek to identify early indicators of brain trauma using MRI

UC Irvine study, UCI, Toshiba, high school football players, cerebral microbleeds, CMB

April 13, 2016 — As chronic traumatic encephalopathy (CTE) stands in the national spotlight for high impact sports, the University of California, Irvine has partnered with Toshiba America Medical Systems Inc. for a first-of-its-kind study of cerebral microbleeds (CMB) in high school football players as a potential precursor to CTE. The study will utilize Toshiba’s Vantage Titan 3T magnetic resonance (MR) system as the key diagnostic tool, taking advantage of its non-invasive capabilities.

The study will investigate the use of non-contrast MRI as a safe and noninvasive way to examine youth athletes and other patients for early signs of CTE, a degenerative disease found in those who suffer head trauma and a well-documented consequence of sub-concussive head injury. This will include evaluations of local high school student volunteers, including 100 test subjects (football players) and 50 control subjects (non-football players). Toshiba will provide application training to UCI researchers concerning the use of Toshiba’s MRI equipment.

“There have not been extensive studies of CTE in younger populations to date, so we see this as an important opportunity to examine if there are precursors or early signs that can lead to better diagnosis and treatment,” said Mark Fisher, M.D., UCI professor of neurology and study lead researcher. “Using Toshiba’s Titan 3T MR system, we may have an effective way to examine how playing football is affecting these subjects, and we hope to break new ground in diagnosing and treating head trauma before it can potentially cause problems for these athletes in the future.”

The Vantage Titan 3T MR was chosen for its ability to provide non-contrast neuro imaging. This includes elements such as a suite of advanced neuro-imaging sequences and Pianissimo noise-reduction technology, and in particular its ability to determine the prevalence of CMB using the Flow Sensitive Black Blood (FSBB) sequence.

For more information: www.uci.edu

Related Content

MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more
SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to